EDAR-Related Hypohidrotic Ectodermal Dysplasia

Genetic MONDO:0016535 Pathograph 9 Ectodermal Dysplasia

Hypohidrotic ectodermal dysplasia caused by mutations in EDAR, which encodes the ectodysplasin A receptor, a TNF receptor superfamily member. EDAR mutations cause both autosomal recessive (HED2, OMIM 224900) and autosomal dominant forms (OMIM 129490) of hypohidrotic ectodermal dysplasia. The receptor binds ectodysplasin A (EDA) and signals through the adaptor protein EDARADD to activate NF-kB, which is essential for ectodermal placode development. Loss-of-function mutations abolish EDA-EDAR-NF-kB signaling, leading to absent or hypoplastic sweat glands, sparse hair, and oligodontia with conical teeth. The clinical phenotype closely resembles X-linked HED caused by EDA mutations, but inheritance differs. Dominant-negative EDAR mutations produce a milder phenotype. EDAR accounts for approximately 25% of non-EDA HED cases.

Ask OpenScientist

Ask a research question about EDAR-Related Hypohidrotic Ectodermal Dysplasia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

5
Pathophys.
15
Phenotypes
9
Pathograph
1
Genes
3
Treatments
2
Subtypes
1
References
1
Deep Research
◆

Subtypes

2
Autosomal Recessive HED (HED2) MONDO:0016619
Classic autosomal recessive form caused by biallelic loss-of-function mutations in EDAR. Phenotype closely resembles X-linked HED (EDA mutations) with severe hypohidrosis, oligodontia, and sparse hair. Homozygous or compound heterozygous mutations completely abolish EDAR signaling.
Autosomal Dominant HED MONDO:0015884
Autosomal dominant form caused by heterozygous EDAR mutations, often with dominant-negative effects. Phenotype is typically milder than the recessive form, with variable expressivity. Dominant mutations cluster in the death domain (exon 12) and interfere with EDARADD recruitment.
⚙

Pathophysiology

5
EDAR Loss-of-Function Disrupts NF-kB Signaling
EDAR is a type I transmembrane receptor of the TNF receptor superfamily that binds ectodysplasin A (EDA). Upon ligand binding, EDAR recruits the adaptor protein EDARADD via its intracellular death domain, which activates the NF-kB signaling cascade. Biallelic loss-of-function EDAR mutations (AR) prevent ligand binding or adaptor recruitment, abolishing downstream NF-kB activation required for ectodermal appendage initiation and morphogenesis.
surface ectodermal cell link keratinocyte link
EDAR link
Canonical NF-kappaB Signaling link ↓ DECREASED Ectodermal Placode Development link ↓ DECREASED
Downstream
Sweat Gland Aplasia/Hypoplasia
Hair Follicle Deficiency
Tooth Developmental Defects
Show evidence (6 references)
PMID:11570810 SUPPORT In Vitro
"We have analyzed the response of Edar signaling in transfected cells and show that it activates nuclear factor-kappaB (NF-kappaB) in a dose-dependent manner."
Demonstrates that EDAR activates NF-kappaB signaling in transfected cells.
PMID:11570810 SUPPORT In Vitro
"The activation of NF-kappaB was greatly reduced in cells expressing mutant forms of Edar associated with the downless phenotype."
Shows that HED-associated EDAR mutations reduce NF-kappaB activation, confirming loss-of-function mechanism.
PMID:11780064 SUPPORT Model Organism
"Edar is a death domain protein of the TNFR family that is required for the development of hair, teeth and other ectodermal derivatives. Mutations in Edar-or its ligand, Eda-cause hypohidrotic ectodermal dysplasia in humans and mice. This disorder is characterized by sparse hair, a lack of sweat..."
Establishes the EDAR death domain as essential for ectodermal development and links EDAR mutations to HED pathogenesis through EDARADD recruitment.
+ 3 more references
Dominant-Negative EDAR Mechanism
Heterozygous EDAR mutations, primarily in the death domain (exon 12), produce a dominant-negative effect in AD-HED. Mutant EDAR binds wild-type EDAR but cannot recruit EDARADD, suppressing NF-kB activation from the wild-type allele. The subcellular localization of dominant-negative alleles differs dramatically from recessive or wild-type alleles, explaining the different mode of inheritance.
Canonical NF-kappaB Signaling link ↓ DECREASED
Downstream
Sweat Gland Aplasia/Hypoplasia
Hair Follicle Deficiency
Tooth Developmental Defects
Show evidence (3 references)
PMID:31245878 SUPPORT In Vitro
"the p.F398* mutant EDAR completely lost its affinity to EDARADD, and suppressed the downstream nuclear factor-κB activation induced by wild-type EDAR in a dominant-negative manner."
Demonstrates dominant-negative mechanism: mutant EDAR suppresses wild-type EDAR signaling.
PMID:31245878 SUPPORT In Vitro
"the mutant EDAR was capable of binding with the wild-type EDAR, which led to reduced interaction between the wild-type EDAR and EDARADD."
Mutant-wild-type EDAR heterodimerization reduces EDARADD recruitment, explaining dominant-negative inheritance.
PMID:11570810 SUPPORT In Vitro
"the subcellular localization of dominant negative alleles of downless is dramatically different from that of recessive or wild-type alleles. This together with differences in NF-kappaB responses suggests an explanation for the different mode of inheritance of the different downless alleles."
Altered subcellular localization of dominant-negative alleles explains the different inheritance mode.
Sweat Gland Aplasia/Hypoplasia
Absence or severe reduction of eccrine sweat glands due to failed ectodermal placode initiation. EDAR-mediated NF-kB signaling is required for sweat gland placode formation; without it, sweat glands fail to develop, resulting in hypohidrosis or anhidrosis and impaired thermoregulation.
epithelial cell of sweat gland link
Sweat Gland Development link ↓ DECREASED Sweat Gland Placode Formation link ↓ DECREASED
Show evidence (1 reference)
PMID:20301291 SUPPORT Human Clinical
"Sweating, although present, is greatly deficient, leading to episodes of hyperthermia until the affected individual or family acquires experience with environmental modifications to control temperature."
GeneReviews describes the characteristic sweating deficiency in HED, linking it to hyperthermia risk.
Hair Follicle Deficiency
Sparse, thin hair results from impaired hair follicle morphogenesis. EDA-EDAR-NF-kB signaling is required for hair follicle placode induction and subsequent follicle development. Loss of EDAR leads to reduced hair follicle density and abnormal hair shaft structure.
hair follicle cell link
Hair Follicle Development link ↓ DECREASED Hair Follicle Placode Formation link ↓ DECREASED
Show evidence (1 reference)
PMID:20301291 SUPPORT Human Clinical
"The scalp hair is thin, lightly pigmented, and slow growing."
GeneReviews description of characteristic hair findings in HED.
Tooth Developmental Defects
Oligodontia and conical tooth morphology result from defective tooth placode initiation and morphogenesis. EDAR signaling through NF-kB is critical for the epithelial-mesenchymal interactions that drive odontogenesis. Absent EDAR signaling leads to missing teeth and abnormal crown shape.
Odontogenesis link ↓ DECREASED
Show evidence (2 references)
PMID:20301291 SUPPORT Human Clinical
"Only a few abnormally formed teeth erupt, at a later-than-average age."
GeneReviews describes the oligodontia and abnormal tooth morphology characteristic of HED.
PMID:37077539 SUPPORT Human Clinical
"EDA, EDAR, and EDARADD play essential roles in ectodermal organ development. As members of the EDA/EDAR/NF-κB signaling pathway, mutations in these genes have been implicated in the pathogenesis of NSTA, as well as hypohidrotic ectodermal dysplasia (HED), a rare genetic disorder that affects..."
Review confirming the role of EDA/EDAR/NF-kB pathway in tooth development and the overlap between tooth agenesis and HED.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for EDAR-Related Hypohidrotic Ectodermal Dysplasia Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

15
Cardiovascular 1
Dry Eye Keratoconjunctivitis sicca (HP:0001097)
Show evidence (1 reference)
PMID:20301291 SUPPORT Human Clinical
"Lubrication eye drops."
GeneReviews management explicitly recommends lubrication eye drops, indicating dry eye / keratoconjunctivitis sicca is a recognized manifestation of HED requiring routine ophthalmologic care.
Head and Neck 3
Oligodontia VERY_FREQUENT Oligodontia (HP:0000677)
Show evidence (2 references)
PMID:20301291 SUPPORT Human Clinical
"Hypohidrotic ectodermal dysplasia (HED) is characterized by hypotrichosis (sparseness of scalp and body hair), hypohidrosis (reduced ability to sweat), and hypodontia (congenital absence of teeth)."
GeneReviews identifies hypodontia/oligodontia as a cardinal feature.
PMID:32819890 SUPPORT Human Clinical
"Hypohidrotic ectodermal dysplasia (HED) is a congenital anomaly characterized by hypohydrosis, hypotrichosis and hypodontia."
Confirms the classic triad including tooth absence in EDAR-specific HED families.
Frontal Bossing Frontal bossing (HP:0002007)
Show evidence (1 reference)
PMID:33205897 SUPPORT Human Clinical
"Additional dysmorphic features may be associated with HED, including frontal bossing, an everted nose, prominent thick lips, a pointed chin, rings under the eyes"
Frontal bossing listed among characteristic dysmorphic features of HED.
Depressed Nasal Bridge Depressed nasal bridge (HP:0005280)
Show evidence (1 reference)
PMID:36138666 SUPPORT Human Clinical
"Patients with HED have characteristic facies with periorbital hyperpigmentation, depressed nasal bridge, malar hypoplasia, and absent or sparse eyebrows and eyelashes."
Review explicitly lists depressed nasal bridge as a characteristic facial feature of HED.
Immune 1
Recurrent Respiratory Infections Recurrent respiratory infections (HP:0002205)
Show evidence (1 reference)
PMID:20301291 SUPPORT Human Clinical
"Management of recurrent respiratory infections and asthma per primary care provider with referral to allergist and/or pulmonologist as needed."
GeneReviews management section confirms recurrent respiratory infections as a feature requiring clinical management.
Integument 4
Hypohidrosis VERY_FREQUENT Hypohidrosis (HP:0000966)
Show evidence (2 references)
PMID:20301291 SUPPORT Human Clinical
"Hypohidrotic ectodermal dysplasia (HED) is characterized by hypotrichosis (sparseness of scalp and body hair), hypohidrosis (reduced ability to sweat), and hypodontia (congenital absence of teeth)."
GeneReviews identifies hypohidrosis as a defining feature of HED.
PMID:31310406 SUPPORT Human Clinical
"They have no resistance to heat as a result of abnormal sweat glands."
Clinical description of EDAR-related HED in Kashmiri families confirms absent sweat gland function.
Dry Skin Dry skin (HP:0000958)
Show evidence (1 reference)
PMID:20301291 SUPPORT Human Clinical
"Skin care products for eczema and exposures that exacerbate dry skin."
GeneReviews management section confirms dry skin as a feature requiring treatment in HED.
Sparse Hair VERY_FREQUENT Sparse hair (HP:0008070)
Show evidence (2 references)
PMID:20301291 SUPPORT Human Clinical
"The scalp hair is thin, lightly pigmented, and slow growing."
GeneReviews description of the hair phenotype in HED.
PMID:31310406 SUPPORT Human Clinical
"These patients have sparse hair on the whole body, including the scalp"
Clinical observation in EDAR-specific HED families confirming sparse hair phenotype.
Nail Dysplasia OCCASIONAL Nail dysplasia (HP:0002164)
Show evidence (1 reference)
PMID:33205897 SUPPORT Human Clinical
"She exhibited her first tooth at 14 months, regular bowel and nail dysplasia of the big toes at the base."
Case report of EDAR mutation carrier showing nail dysplasia, confirming it as an occasional feature.
Metabolism 1
Heat Intolerance VERY_FREQUENT Heat intolerance (HP:0002046)
Show evidence (1 reference)
PMID:20301291 SUPPORT Human Clinical
"Sweating, although present, is greatly deficient, leading to episodes of hyperthermia until the affected individual or family acquires experience with environmental modifications to control temperature."
GeneReviews confirms heat intolerance and hyperthermia episodes as consequences of sweat gland deficiency.
Other 5
Sparse Eyebrows Sparse eyebrow (HP:0045075)
Show evidence (2 references)
PMID:36138666 SUPPORT Human Clinical
"Patients with HED have characteristic facies with periorbital hyperpigmentation, depressed nasal bridge, malar hypoplasia, and absent or sparse eyebrows and eyelashes."
Review of HED ocular phenotype lists sparse eyebrows as a characteristic facial feature.
PMID:38840186 SUPPORT Human Clinical
"The elder had a very sparse dark and brittle hair, sparse eyebrows and eyelashes, conical upper and lower premolar teeth with hypodontia"
Case report of siblings with HED (EDARADD pathway) showing sparse eyebrows as a clinical feature.
Sparse Eyelashes Sparse eyelashes (HP:0000653)
Show evidence (2 references)
PMID:36138666 SUPPORT Human Clinical
"Patients with HED have characteristic facies with periorbital hyperpigmentation, depressed nasal bridge, malar hypoplasia, and absent or sparse eyebrows and eyelashes."
Review of HED ocular phenotype lists sparse eyelashes as a characteristic facial feature.
PMID:38840186 SUPPORT Human Clinical
"sparse eyebrows and eyelashes, conical upper and lower premolar teeth with hypodontia, widely spaced teeth, very dry skin"
Case report confirms sparse eyelashes in HED siblings.
Conical Teeth VERY_FREQUENT Small, conical teeth (HP:0200141)
Show evidence (1 reference)
PMID:33205897 SUPPORT Human Clinical
"Sparse hair (hypotrichosis), abnormal or missing teeth (anodontia or hypodontia), and reduced ability of eccrine sweat glands (hypohidrosis) are the main signs of the disorder"
Confirms abnormal tooth morphology as a main sign of HED.
Periorbital Hyperpigmentation Periorbital hyperpigmentation (HP:0001106)
Show evidence (1 reference)
PMID:33205897 SUPPORT Human Clinical
"frontal bossing, an everted nose, prominent thick lips, a pointed chin, rings under the eyes"
Periorbital darkening (rings under the eyes) listed as a characteristic facial feature.
Nasal and Aural Concretions Abnormal nasal mucus secretion (HP:0031416)
Show evidence (1 reference)
PMID:20301291 SUPPORT Human Clinical
"Nasal and aural concretions may be removed with suction devices or forceps as needed by an otolaryngologist."
GeneReviews management explicitly describes nasal and aural concretions requiring otolaryngologic intervention, identifying this as a recognized HED manifestation.
🧬

Genetic Associations

1
EDAR Loss-of-Function Mutations (Pathogenic Variants)
Autosomal Recessive Autosomal Dominant
Show evidence (7 references)
PMID:10431241 SUPPORT Human Clinical
"The putative protein is predicted to have a single transmembrane domain, and shows similarity to two separate domains of the tumour necrosis factor receptor (TNFR) family."
Original identification of EDAR as a TNFR family member causing AR and AD HED.
PMID:16435307 SUPPORT Human Clinical
"Our study demonstrates that EDAR is implicated in about 25% of non-ED1 HED, and may account for both autosomal-dominant and -recessive forms."
Establishes EDAR as responsible for ~25% of non-X-linked HED cases.
PMID:41645317 SUPPORT Human Clinical
"The distribution of mutated genes was as follows: EDA (n = 155, 84.7%), WNT10A (n = 16, 8.8%), and EDAR (n = 12, 6.5%)."
Largest HED cohort study (261 families) showing EDAR accounts for 6.5% of all HED cases.
+ 4 more references
💊

Treatments

3
Symptomatic Management of Hypohidrosis
Action: supportive care MAXO:0000950
Environmental modifications to prevent overheating including cooling vests, air conditioning, and avoidance of excessive physical exertion in heat. Access to adequate water supply and cool environments during hot weather is essential.
Show evidence (1 reference)
PMID:20301291 SUPPORT Human Clinical
"Access to an adequate water supply and a cool environment during hot weather."
GeneReviews management recommendation for hypohidrosis.
Dental Rehabilitation
Action: denture usage MAXO:0001533
Prosthetic dental treatment including removable dentures in childhood, bonding of conical teeth, orthodontics, and dental implants in adulthood to address oligodontia and abnormal tooth morphology.
Show evidence (1 reference)
PMID:20301291 SUPPORT Human Clinical
"Early dental treatment; bonding of conical teeth; orthodontics as necessary; dental implants in the anterior portion of the mandibular arch in older children; replacement of dental prostheses as needed, often every 2.5 years; dental implants in adults"
GeneReviews comprehensive dental management strategy for HED.
Genetic Counseling
Action: genetic counseling MAXO:0000079
Genetic counseling for families to determine inheritance pattern (AR vs AD) and recurrence risk. Identification of the specific EDAR pathogenic variant enables prenatal and preimplantation genetic testing.
Show evidence (2 references)
PMID:20301291 SUPPORT Human Clinical
"EDAR-, EDARADD-, and WNT10A-related HED are inherited in an autosomal recessive or an autosomal dominant manner."
GeneReviews confirms the dual inheritance pattern requiring careful genetic counseling.
PMID:32819890 SUPPORT Human Clinical
"The three variants reported here expand the spectrum of EDAR mutations associated with HED which may further facilitate genetic counselling of families segregating with similar disorders in the Pakistani population."
Expanding variant spectrum supports importance of genetic counseling in diverse populations.
{ }

Source YAML

click to show 
name: EDAR-Related Hypohidrotic Ectodermal Dysplasia
creation_date: "2026-04-24T00:00:00Z"
updated_date: "2026-04-24T00:00:00Z"
description: >-
  Hypohidrotic ectodermal dysplasia caused by mutations in EDAR, which encodes
  the ectodysplasin A receptor, a TNF receptor superfamily member. EDAR
  mutations cause both autosomal recessive (HED2, OMIM 224900) and autosomal
  dominant forms (OMIM 129490) of hypohidrotic ectodermal dysplasia. The
  receptor binds ectodysplasin A (EDA) and signals through the adaptor protein
  EDARADD to activate NF-kB, which is essential for ectodermal placode
  development. Loss-of-function mutations abolish EDA-EDAR-NF-kB signaling,
  leading to absent or hypoplastic sweat glands, sparse hair, and oligodontia
  with conical teeth. The clinical phenotype closely resembles X-linked HED
  caused by EDA mutations, but inheritance differs. Dominant-negative EDAR
  mutations produce a milder phenotype. EDAR accounts for approximately 25%
  of non-EDA HED cases.
category: Genetic
parents:
- Ectodermal Dysplasia
disease_term:
  preferred_term: EDAR-related hypohidrotic ectodermal dysplasia
  term:
    id: MONDO:0016535
    label: hypohidrotic ectodermal dysplasia
has_subtypes:
- name: AR
  display_name: Autosomal Recessive HED (HED2)
  description: >-
    Classic autosomal recessive form caused by biallelic loss-of-function
    mutations in EDAR. Phenotype closely resembles X-linked HED (EDA mutations)
    with severe hypohidrosis, oligodontia, and sparse hair. Homozygous or
    compound heterozygous mutations completely abolish EDAR signaling.
  subtype_term:
    preferred_term: autosomal recessive hypohidrotic ectodermal dysplasia
    term:
      id: MONDO:0016619
      label: autosomal recessive hypohidrotic ectodermal dysplasia
- name: AD
  display_name: Autosomal Dominant HED
  description: >-
    Autosomal dominant form caused by heterozygous EDAR mutations, often with
    dominant-negative effects. Phenotype is typically milder than the recessive
    form, with variable expressivity. Dominant mutations cluster in the death
    domain (exon 12) and interfere with EDARADD recruitment.
  subtype_term:
    preferred_term: autosomal dominant hypohidrotic ectodermal dysplasia
    term:
      id: MONDO:0015884
      label: autosomal dominant hypohidrotic ectodermal dysplasia
pathophysiology:
- name: EDAR Loss-of-Function Disrupts NF-kB Signaling
  description: >-
    EDAR is a type I transmembrane receptor of the TNF receptor superfamily that
    binds ectodysplasin A (EDA). Upon ligand binding, EDAR recruits the adaptor
    protein EDARADD via its intracellular death domain, which activates the
    NF-kB signaling cascade. Biallelic loss-of-function EDAR mutations (AR)
    prevent ligand binding or adaptor recruitment, abolishing downstream NF-kB
    activation required for ectodermal appendage initiation and morphogenesis.
  cell_types:
  - preferred_term: surface ectodermal cell
    term:
      id: CL:0000114
      label: surface ectodermal cell
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  biological_processes:
  - preferred_term: Canonical NF-kappaB Signaling
    term:
      id: GO:0007249
      label: canonical NF-kappaB signal transduction
    modifier: DECREASED
  - preferred_term: Ectodermal Placode Development
    term:
      id: GO:0071696
      label: ectodermal placode development
    modifier: DECREASED
  downstream:
  - target: Sweat Gland Aplasia/Hypoplasia
  - target: Hair Follicle Deficiency
  - target: Tooth Developmental Defects
  evidence:
  - reference: PMID:11570810
    reference_title: "Signaling and subcellular localization of the TNF receptor Edar."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We have analyzed the response of Edar signaling in transfected cells and
      show that it activates nuclear factor-kappaB (NF-kappaB) in a
      dose-dependent manner.
    explanation: >-
      Demonstrates that EDAR activates NF-kappaB signaling in transfected
      cells.
  - reference: PMID:11570810
    reference_title: "Signaling and subcellular localization of the TNF receptor Edar."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The activation of NF-kappaB was greatly reduced in cells expressing
      mutant forms of Edar associated with the downless phenotype.
    explanation: >-
      Shows that HED-associated EDAR mutations reduce NF-kappaB activation,
      confirming loss-of-function mechanism.
  - reference: PMID:11780064
    reference_title: "Gene defect in ectodermal dysplasia implicates a death domain adapter in development."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Edar is a death domain protein of the TNFR family that is required for
      the development of hair, teeth and other ectodermal derivatives. Mutations
      in Edar-or its ligand, Eda-cause hypohidrotic ectodermal dysplasia in
      humans and mice. This disorder is characterized by sparse hair, a lack of
      sweat glands and malformation of teeth.
    explanation: >-
      Establishes the EDAR death domain as essential for ectodermal development
      and links EDAR mutations to HED pathogenesis through EDARADD recruitment.
  - reference: PMID:36258277
    reference_title: "Different degree of loss-of-function among four missense mutations in the EDAR gene responsible for autosomal recessive hypohidrotic ectodermal dysplasia may be associated with the phenotypic severity."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      NF-κB reporter assays demonstrated that all the mutant EDAR showed
      reduced activation of NF-κB, but the reduction by p.G382S- and
      p.I388T-mutant EDAR was moderate.
    explanation: >-
      Quantitative in vitro evidence showing graded loss of NF-kB activation
      across different EDAR death domain mutations.
  - reference: PMID:36765055
    reference_title: "Structural insights into pathogenic mechanism of hypohidrotic ectodermal dysplasia caused by ectodysplasin A variants."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      we report the crystal structure of EDA C-terminal TNF homology domain
      bound to the N-terminal cysteine-rich domains of EDAR.
    explanation: >-
      Crystal structure of EDA-EDAR complex (2.8 A resolution) provides
      atomic-level explanation for how variants disrupt ligand-receptor
      binding.
  - reference: PMID:36765055
    reference_title: "Structural insights into pathogenic mechanism of hypohidrotic ectodermal dysplasia caused by ectodysplasin A variants."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      different EDA mutations lead to varying degrees of ectodermal
      developmental defects in mice, which is consistent with the clinical
      observations on human patients.
    explanation: >-
      Mouse genetic studies confirm graded severity of ectodermal defects
      correlating with degree of EDA-EDAR signaling disruption.
  genes:
  - preferred_term: EDAR
    term:
      id: hgnc:2895
      label: EDAR
- name: Dominant-Negative EDAR Mechanism
  description: >-
    Heterozygous EDAR mutations, primarily in the death domain (exon 12),
    produce a dominant-negative effect in AD-HED. Mutant EDAR binds wild-type
    EDAR but cannot recruit EDARADD, suppressing NF-kB activation from the
    wild-type allele. The subcellular localization of dominant-negative alleles
    differs dramatically from recessive or wild-type alleles, explaining the
    different mode of inheritance.
  biological_processes:
  - preferred_term: Canonical NF-kappaB Signaling
    term:
      id: GO:0007249
      label: canonical NF-kappaB signal transduction
    modifier: DECREASED
  downstream:
  - target: Sweat Gland Aplasia/Hypoplasia
  - target: Hair Follicle Deficiency
  - target: Tooth Developmental Defects
  evidence:
  - reference: PMID:31245878
    reference_title: "Functional studies for a dominant mutation in the EDAR gene responsible for hypohidrotic ectodermal dysplasia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      the p.F398* mutant EDAR completely lost its affinity to EDARADD, and
      suppressed the downstream nuclear factor-κB activation induced by
      wild-type EDAR in a dominant-negative manner.
    explanation: >-
      Demonstrates dominant-negative mechanism: mutant EDAR suppresses
      wild-type EDAR signaling.
  - reference: PMID:31245878
    reference_title: "Functional studies for a dominant mutation in the EDAR gene responsible for hypohidrotic ectodermal dysplasia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      the mutant EDAR was capable of binding with the wild-type EDAR, which
      led to reduced interaction between the wild-type EDAR and EDARADD.
    explanation: >-
      Mutant-wild-type EDAR heterodimerization reduces EDARADD recruitment,
      explaining dominant-negative inheritance.
  - reference: PMID:11570810
    reference_title: "Signaling and subcellular localization of the TNF receptor Edar."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      the subcellular localization of dominant negative alleles of downless is
      dramatically different from that of recessive or wild-type alleles. This
      together with differences in NF-kappaB responses suggests an explanation
      for the different mode of inheritance of the different downless alleles.
    explanation: >-
      Altered subcellular localization of dominant-negative alleles explains
      the different inheritance mode.
- name: Sweat Gland Aplasia/Hypoplasia
  description: >-
    Absence or severe reduction of eccrine sweat glands due to failed ectodermal
    placode initiation. EDAR-mediated NF-kB signaling is required for sweat
    gland placode formation; without it, sweat glands fail to develop, resulting
    in hypohidrosis or anhidrosis and impaired thermoregulation.
  cell_types:
  - preferred_term: epithelial cell of sweat gland
    term:
      id: CL:1000448
      label: epithelial cell of sweat gland
  biological_processes:
  - preferred_term: Sweat Gland Development
    term:
      id: GO:0060792
      label: sweat gland development
    modifier: DECREASED
  - preferred_term: Sweat Gland Placode Formation
    term:
      id: GO:0060793
      label: sweat gland placode formation
    modifier: DECREASED
  evidence:
  - reference: PMID:20301291
    reference_title: "Hypohidrotic Ectodermal Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sweating, although present, is greatly deficient, leading to episodes of
      hyperthermia until the affected individual or family acquires experience
      with environmental modifications to control temperature.
    explanation: >-
      GeneReviews describes the characteristic sweating deficiency in HED,
      linking it to hyperthermia risk.
- name: Hair Follicle Deficiency
  description: >-
    Sparse, thin hair results from impaired hair follicle morphogenesis.
    EDA-EDAR-NF-kB signaling is required for hair follicle placode induction
    and subsequent follicle development. Loss of EDAR leads to reduced hair
    follicle density and abnormal hair shaft structure.
  cell_types:
  - preferred_term: hair follicle cell
    term:
      id: CL:0002559
      label: hair follicle cell
  biological_processes:
  - preferred_term: Hair Follicle Development
    term:
      id: GO:0001942
      label: hair follicle development
    modifier: DECREASED
  - preferred_term: Hair Follicle Placode Formation
    term:
      id: GO:0060789
      label: hair follicle placode formation
    modifier: DECREASED
  evidence:
  - reference: PMID:20301291
    reference_title: "Hypohidrotic Ectodermal Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The scalp hair is thin, lightly pigmented, and slow growing.
    explanation: >-
      GeneReviews description of characteristic hair findings in HED.
- name: Tooth Developmental Defects
  description: >-
    Oligodontia and conical tooth morphology result from defective tooth
    placode initiation and morphogenesis. EDAR signaling through NF-kB
    is critical for the epithelial-mesenchymal interactions that drive
    odontogenesis. Absent EDAR signaling leads to missing teeth and
    abnormal crown shape.
  biological_processes:
  - preferred_term: Odontogenesis
    term:
      id: GO:0042476
      label: odontogenesis
    modifier: DECREASED
  evidence:
  - reference: PMID:20301291
    reference_title: "Hypohidrotic Ectodermal Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Only a few abnormally formed teeth erupt, at a later-than-average age.
    explanation: >-
      GeneReviews describes the oligodontia and abnormal tooth morphology
      characteristic of HED.
  - reference: PMID:37077539
    reference_title: "The EDA/EDAR/NF-κB pathway in non-syndromic tooth agenesis: A genetic perspective."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      EDA, EDAR, and EDARADD play essential roles in ectodermal organ
      development. As members of the EDA/EDAR/NF-κB signaling pathway,
      mutations in these genes have been implicated in the pathogenesis of
      NSTA, as well as hypohidrotic ectodermal dysplasia (HED), a rare
      genetic disorder that affects multiple ectodermal structures, including
      teeth.
    explanation: >-
      Review confirming the role of EDA/EDAR/NF-kB pathway in tooth
      development and the overlap between tooth agenesis and HED.
phenotypes:
- category: Dermatologic
  name: Hypohidrosis
  frequency: VERY_FREQUENT
  description: >-
    Reduced or absent sweating due to aplasia or hypoplasia of eccrine sweat
    glands. This is the cardinal feature leading to heat intolerance and
    potentially life-threatening hyperthermia in infancy.
  phenotype_term:
    preferred_term: Hypohidrosis
    term:
      id: HP:0000966
      label: Hypohidrosis
  evidence:
  - reference: PMID:20301291
    reference_title: "Hypohidrotic Ectodermal Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hypohidrotic ectodermal dysplasia (HED) is characterized by
      hypotrichosis (sparseness of scalp and body hair), hypohidrosis (reduced
      ability to sweat), and hypodontia (congenital absence of teeth).
    explanation: >-
      GeneReviews identifies hypohidrosis as a defining feature of HED.
  - reference: PMID:31310406
    reference_title: "A recurrent missense mutation in the EDAR gene causes severe autosomal recessive hypohidrotic ectodermal dysplasia in two consanguineous Kashmiri families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They have no resistance to heat as a result of abnormal sweat glands.
    explanation: >-
      Clinical description of EDAR-related HED in Kashmiri families confirms
      absent sweat gland function.
- category: Dermatologic
  name: Dry Skin
  description: >-
    Generalized xerosis due to reduced sweat and sebaceous gland function.
  phenotype_term:
    preferred_term: Dry skin
    term:
      id: HP:0000958
      label: Dry skin
  evidence:
  - reference: PMID:20301291
    reference_title: "Hypohidrotic Ectodermal Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Skin care products for eczema and exposures that exacerbate dry skin.
    explanation: >-
      GeneReviews management section confirms dry skin as a feature requiring
      treatment in HED.
- category: Dermatologic
  name: Sparse Hair
  frequency: VERY_FREQUENT
  description: >-
    Scalp and body hair is sparse, thin, lightly pigmented, and slow-growing
    due to reduced hair follicle density.
  phenotype_term:
    preferred_term: Sparse hair
    term:
      id: HP:0008070
      label: Sparse hair
  evidence:
  - reference: PMID:20301291
    reference_title: "Hypohidrotic Ectodermal Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The scalp hair is thin, lightly pigmented, and slow growing.
    explanation: >-
      GeneReviews description of the hair phenotype in HED.
  - reference: PMID:31310406
    reference_title: "A recurrent missense mutation in the EDAR gene causes severe autosomal recessive hypohidrotic ectodermal dysplasia in two consanguineous Kashmiri families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These patients have sparse hair on the whole body, including the scalp
    explanation: >-
      Clinical observation in EDAR-specific HED families confirming sparse
      hair phenotype.
- category: Dermatologic
  name: Sparse Eyebrows
  description: >-
    Eyebrows are thin or partially absent.
  phenotype_term:
    preferred_term: Sparse eyebrow
    term:
      id: HP:0045075
      label: Sparse eyebrow
  evidence:
  - reference: PMID:36138666
    reference_title: "Extended Overview of Ocular Phenotype with Recent Advances in Hypohidrotic Ectodermal Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with HED have characteristic facies with periorbital
      hyperpigmentation, depressed nasal bridge, malar hypoplasia, and absent or
      sparse eyebrows and eyelashes.
    explanation: >-
      Review of HED ocular phenotype lists sparse eyebrows as a
      characteristic facial feature.
  - reference: PMID:38840186
    reference_title: "Novel homozygous frameshift insertion variant in the last exon of the EDARADD causing hypohidrotic ectodermal dysplasia in two siblings: case report and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The elder had a very sparse dark and brittle hair, sparse eyebrows and
      eyelashes, conical upper and lower premolar teeth with hypodontia
    explanation: >-
      Case report of siblings with HED (EDARADD pathway) showing sparse
      eyebrows as a clinical feature.
- category: Dermatologic
  name: Sparse Eyelashes
  description: >-
    Eyelashes are thin or absent.
  phenotype_term:
    preferred_term: Sparse eyelashes
    term:
      id: HP:0000653
      label: Sparse eyelashes
  evidence:
  - reference: PMID:36138666
    reference_title: "Extended Overview of Ocular Phenotype with Recent Advances in Hypohidrotic Ectodermal Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with HED have characteristic facies with periorbital
      hyperpigmentation, depressed nasal bridge, malar hypoplasia, and absent or
      sparse eyebrows and eyelashes.
    explanation: >-
      Review of HED ocular phenotype lists sparse eyelashes as a
      characteristic facial feature.
  - reference: PMID:38840186
    reference_title: "Novel homozygous frameshift insertion variant in the last exon of the EDARADD causing hypohidrotic ectodermal dysplasia in two siblings: case report and review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      sparse eyebrows and eyelashes, conical upper and lower premolar teeth
      with hypodontia, widely spaced teeth, very dry skin
    explanation: >-
      Case report confirms sparse eyelashes in HED siblings.
- category: Dental
  name: Oligodontia
  frequency: VERY_FREQUENT
  description: >-
    Congenital absence of six or more permanent teeth. One of the most
    consistent features of HED.
  phenotype_term:
    preferred_term: Oligodontia
    term:
      id: HP:0000677
      label: Oligodontia
  evidence:
  - reference: PMID:20301291
    reference_title: "Hypohidrotic Ectodermal Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hypohidrotic ectodermal dysplasia (HED) is characterized by
      hypotrichosis (sparseness of scalp and body hair), hypohidrosis (reduced
      ability to sweat), and hypodontia (congenital absence of teeth).
    explanation: >-
      GeneReviews identifies hypodontia/oligodontia as a cardinal feature.
  - reference: PMID:32819890
    reference_title: "Homozygous variants of EDAR underlying hypohidrotic ectodermal dysplasia in three consanguineous families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hypohidrotic ectodermal dysplasia (HED) is a congenital anomaly
      characterized by hypohydrosis, hypotrichosis and hypodontia.
    explanation: >-
      Confirms the classic triad including tooth absence in EDAR-specific
      HED families.
- category: Dental
  name: Conical Teeth
  frequency: VERY_FREQUENT
  description: >-
    Remaining teeth have a characteristic conical or peg-shaped morphology.
  phenotype_term:
    preferred_term: Small, conical teeth
    term:
      id: HP:0200141
      label: Small, conical teeth
  evidence:
  - reference: PMID:33205897
    reference_title: "Missense mutations in EDA and EDAR genes cause dominant syndromic tooth agenesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sparse hair (hypotrichosis), abnormal or missing teeth (anodontia or
      hypodontia), and reduced ability of eccrine sweat glands (hypohidrosis)
      are the main signs of the disorder
    explanation: >-
      Confirms abnormal tooth morphology as a main sign of HED.
- category: Craniofacial
  name: Frontal Bossing
  description: >-
    Prominent forehead giving a characteristic facial appearance.
  phenotype_term:
    preferred_term: Frontal bossing
    term:
      id: HP:0002007
      label: Frontal bossing
  evidence:
  - reference: PMID:33205897
    reference_title: "Missense mutations in EDA and EDAR genes cause dominant syndromic tooth agenesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additional dysmorphic features may be associated with HED, including
      frontal bossing, an everted nose, prominent thick lips, a pointed chin,
      rings under the eyes
    explanation: >-
      Frontal bossing listed among characteristic dysmorphic features of HED.
- category: Craniofacial
  name: Depressed Nasal Bridge
  description: >-
    Flattened or depressed nasal bridge contributing to the characteristic
    facies of HED.
  phenotype_term:
    preferred_term: Depressed nasal bridge
    term:
      id: HP:0005280
      label: Depressed nasal bridge
  evidence:
  - reference: PMID:36138666
    reference_title: "Extended Overview of Ocular Phenotype with Recent Advances in Hypohidrotic Ectodermal Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with HED have characteristic facies with periorbital
      hyperpigmentation, depressed nasal bridge, malar hypoplasia, and absent or
      sparse eyebrows and eyelashes.
    explanation: >-
      Review explicitly lists depressed nasal bridge as a characteristic
      facial feature of HED.
- category: Craniofacial
  name: Periorbital Hyperpigmentation
  description: >-
    Dark circles around the eyes, a characteristic feature of the HED facies.
  phenotype_term:
    preferred_term: Periorbital hyperpigmentation
    term:
      id: HP:0001106
      label: Periorbital hyperpigmentation
  evidence:
  - reference: PMID:33205897
    reference_title: "Missense mutations in EDA and EDAR genes cause dominant syndromic tooth agenesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      frontal bossing, an everted nose, prominent thick lips, a pointed chin,
      rings under the eyes
    explanation: >-
      Periorbital darkening (rings under the eyes) listed as a characteristic
      facial feature.
- category: Systemic
  name: Heat Intolerance
  frequency: VERY_FREQUENT
  description: >-
    Inability to tolerate heat due to impaired sweating. May lead to
    life-threatening hyperthermia, particularly in young children.
  phenotype_term:
    preferred_term: Heat intolerance
    term:
      id: HP:0002046
      label: Heat intolerance
  evidence:
  - reference: PMID:20301291
    reference_title: "Hypohidrotic Ectodermal Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sweating, although present, is greatly deficient, leading to episodes of
      hyperthermia until the affected individual or family acquires experience
      with environmental modifications to control temperature.
    explanation: >-
      GeneReviews confirms heat intolerance and hyperthermia episodes as
      consequences of sweat gland deficiency.
- category: Respiratory
  name: Recurrent Respiratory Infections
  description: >-
    Frequent upper and lower respiratory tract infections due to impaired
    mucosal gland function and deficient nasal secretions.
  phenotype_term:
    preferred_term: Recurrent respiratory infections
    term:
      id: HP:0002205
      label: Recurrent respiratory infections
  evidence:
  - reference: PMID:20301291
    reference_title: "Hypohidrotic Ectodermal Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Management of recurrent respiratory infections and asthma per primary
      care provider with referral to allergist and/or pulmonologist as needed.
    explanation: >-
      GeneReviews management section confirms recurrent respiratory infections
      as a feature requiring clinical management.
- category: Dermatologic
  name: Nail Dysplasia
  frequency: OCCASIONAL
  description: >-
    Fingernails and toenails may be thin, brittle, or dystrophic.
  phenotype_term:
    preferred_term: Nail dysplasia
    term:
      id: HP:0002164
      label: Nail dysplasia
  evidence:
  - reference: PMID:33205897
    reference_title: "Missense mutations in EDA and EDAR genes cause dominant syndromic tooth agenesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      She exhibited her first tooth at 14 months, regular bowel and nail
      dysplasia of the big toes at the base.
    explanation: >-
      Case report of EDAR mutation carrier showing nail dysplasia,
      confirming it as an occasional feature.
- category: Ophthalmologic
  name: Dry Eye
  description: >-
    Reduced lacrimal gland secretion produces dry eye / keratoconjunctivitis
    sicca, requiring lubrication eye drops as part of routine HED management.
  phenotype_term:
    preferred_term: Keratoconjunctivitis sicca
    term:
      id: HP:0001097
      label: Keratoconjunctivitis sicca
  evidence:
  - reference: PMID:20301291
    reference_title: "Hypohidrotic Ectodermal Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Lubrication eye drops.
    explanation: >-
      GeneReviews management explicitly recommends lubrication eye drops,
      indicating dry eye / keratoconjunctivitis sicca is a recognized
      manifestation of HED requiring routine ophthalmologic care.
- category: Otolaryngologic
  name: Nasal and Aural Concretions
  description: >-
    Abnormal nasal mucus secretion in HED leads to dried mucus concretions
    in the nasal cavity and external ear canal, requiring periodic removal
    by suction or forceps. Reduced mucosal gland output and altered mucus
    composition are the presumed mechanism.
  phenotype_term:
    preferred_term: Abnormal nasal mucus secretion
    term:
      id: HP:0031416
      label: Abnormal nasal mucus secretion
  evidence:
  - reference: PMID:20301291
    reference_title: "Hypohidrotic Ectodermal Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Nasal and aural concretions may be removed with suction devices or
      forceps as needed by an otolaryngologist.
    explanation: >-
      GeneReviews management explicitly describes nasal and aural
      concretions requiring otolaryngologic intervention, identifying
      this as a recognized HED manifestation.
genetic:
- name: EDAR Loss-of-Function Mutations
  association: Pathogenic Variants
  gene_term:
    preferred_term: EDAR
    term:
      id: hgnc:2895
      label: EDAR
  inheritance:
  - name: Autosomal Recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
    evidence:
    - reference: PMID:10431241
      reference_title: "Mutations in the human homologue of mouse dl cause autosomal recessive and dominant hypohidrotic ectodermal dysplasia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We isolated and characterized its human DL homologue, and identified
        mutations in three families displaying recessive inheritance and two
        with dominant inheritance.
      explanation: >-
        Landmark paper identifying EDAR mutations as the cause of both AR
        and AD HED in human families.
  - name: Autosomal Dominant
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
    evidence:
    - reference: PMID:10431241
      reference_title: "Mutations in the human homologue of mouse dl cause autosomal recessive and dominant hypohidrotic ectodermal dysplasia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We isolated and characterized its human DL homologue, and identified
        mutations in three families displaying recessive inheritance and two
        with dominant inheritance.
      explanation: >-
        Same landmark paper establishing both modes of inheritance for EDAR
        mutations.
  features: >-
    Biallelic (AR) or heterozygous dominant-negative (AD) mutations in EDAR
    (2q11-q13). The gene encodes a TNF receptor superfamily member with an
    extracellular ligand-binding domain, transmembrane domain, and intracellular
    death domain. Missense mutations in the ligand-binding domain (extracellular
    TNFR domain) prevent EDA binding; mutations in the death domain (exon 12)
    prevent EDARADD recruitment and produce dominant-negative effects. Recessive
    mutations are found throughout the gene; dominant mutations cluster in the
    death domain. EDAR accounts for approximately 6.5% of all HED and about 25%
    of non-EDA HED.
  evidence:
  - reference: PMID:10431241
    reference_title: "Mutations in the human homologue of mouse dl cause autosomal recessive and dominant hypohidrotic ectodermal dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The putative protein is predicted to have a single transmembrane domain,
      and shows similarity to two separate domains of the tumour necrosis
      factor receptor (TNFR) family.
    explanation: >-
      Original identification of EDAR as a TNFR family member causing AR
      and AD HED.
  - reference: PMID:16435307
    reference_title: "Mutations in EDAR account for one-quarter of non-ED1-related hypohidrotic ectodermal dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our study demonstrates that EDAR is implicated in about 25% of non-ED1
      HED, and may account for both autosomal-dominant and -recessive forms.
    explanation: >-
      Establishes EDAR as responsible for ~25% of non-X-linked HED cases.
  - reference: PMID:41645317
    reference_title: "Mutational spectrum of EDA, EDAR, EDARADD, and WNT10A genes in the largest cohort of Russian patients with hypohidrotic ectodermal dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The distribution of mutated genes was as follows: EDA (n = 155, 84.7%),
      WNT10A (n = 16, 8.8%), and EDAR (n = 12, 6.5%).
    explanation: >-
      Largest HED cohort study (261 families) showing EDAR accounts for 6.5%
      of all HED cases.
  - reference: PMID:31245878
    reference_title: "Functional studies for a dominant mutation in the EDAR gene responsible for hypohidrotic ectodermal dysplasia."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      the p.F398* mutant EDAR completely lost its affinity to EDARADD, and
      suppressed the downstream nuclear factor-κB activation induced by
      wild-type EDAR in a dominant-negative manner.
    explanation: >-
      Demonstrates dominant-negative mechanism of AD EDAR mutations through
      loss of EDARADD binding and suppression of wild-type signaling.
  - reference: PMID:36258277
    reference_title: "Different degree of loss-of-function among four missense mutations in the EDAR gene responsible for autosomal recessive hypohidrotic ectodermal dysplasia may be associated with the phenotypic severity."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      the degree of loss-of-function is different among the mutant EDAR
      proteins, which may be associated with the severity of the disease.
    explanation: >-
      Shows genotype-phenotype correlation with graded loss of function
      correlating with disease severity.
  - reference: PMID:30623979
    reference_title: "Variants of the ectodysplasin A1 receptor gene underlying homozygous cases of autosomal recessive hypohidrotic ectodermal dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autosomal recessive (AR) forms of HED may be caused by pathogenic
      variants of the ectodysplasin A1 receptor (EDAR) gene that encodes a
      receptor involved in the NF-κB signaling pathway.
    explanation: >-
      Confirms EDAR as cause of AR-HED with variants affecting NF-kB
      signaling.
  - reference: PMID:33205897
    reference_title: "Missense mutations in EDA and EDAR genes cause dominant syndromic tooth agenesis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      all the dominant mutations in EDAR described thus far are located in
      the exon 12 encoding the DD
    explanation: >-
      Confirms that dominant EDAR mutations cluster in the death domain
      (exon 12), while extracellular domain mutations are recessive.
  variants:
  - name: p.Arg420Trp
    description: >-
      Missense variant in the death domain showing variable expressivity
      from isolated tooth agenesis to full HED phenotype.
    evidence:
    - reference: PMID:30623979
      reference_title: "Variants of the ectodysplasin A1 receptor gene underlying homozygous cases of autosomal recessive hypohidrotic ectodermal dysplasia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The same missense variant, c.1258C>T (p.Arg420Trp), has actually been
        reported to be restricted to the Icelandic population and to be
        associated with non-syndromic tooth agenesis but not HED. As our
        patient has no known relationship to Icelandic individuals and displays
        a rather severe HED phenotype, we suggest that EDAR-Arg420Trp is a
        more widespread variant, possibly with variable clinical expressivity.
      explanation: >-
        Demonstrates variable expressivity of EDAR death domain variants,
        ranging from isolated tooth agenesis to full HED.
  - name: p.W434R
    description: >-
      Recurrent homozygous missense variant in exon 12 causing severe AR-HED,
      identified in consanguineous Kashmiri families.
    evidence:
    - reference: PMID:31310406
      reference_title: "A recurrent missense mutation in the EDAR gene causes severe autosomal recessive hypohidrotic ectodermal dysplasia in two consanguineous Kashmiri families."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We identified an already known rare homozygous missense (NM_022336
        c.1300 T>C; p.W434R; minor allele frequency 0.00007) variant in
        exon 12 of the EDAR gene.
      explanation: >-
        Recurrent mutation in two unrelated families confirms pathogenicity.
  - name: p.Phe96Ser
    description: >-
      Novel missense variant in the extracellular ligand-binding domain causing
      AD-HED, demonstrating that some extracellular domain mutations can also
      have dominant effects.
    evidence:
    - reference: PMID:33205897
      reference_title: "Missense mutations in EDA and EDAR genes cause dominant syndromic tooth agenesis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        A novel missense variant was identified in the EDAR (c.287T>C,
        p.Phe96Ser) of a female child proband and her mother, accounting for
        autosomal dominant HED.
      explanation: >-
        First report of a dominant EDAR mutation in the extracellular domain,
        expanding understanding of domain-inheritance correlations.
treatments:
- name: Symptomatic Management of Hypohidrosis
  description: >-
    Environmental modifications to prevent overheating including cooling vests,
    air conditioning, and avoidance of excessive physical exertion in heat.
    Access to adequate water supply and cool environments during hot weather
    is essential.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:20301291
    reference_title: "Hypohidrotic Ectodermal Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Access to an adequate water supply and a cool environment during hot
      weather.
    explanation: >-
      GeneReviews management recommendation for hypohidrosis.
- name: Dental Rehabilitation
  description: >-
    Prosthetic dental treatment including removable dentures in childhood,
    bonding of conical teeth, orthodontics, and dental implants in adulthood
    to address oligodontia and abnormal tooth morphology.
  treatment_term:
    preferred_term: denture usage
    term:
      id: MAXO:0001533
      label: denture usage
  evidence:
  - reference: PMID:20301291
    reference_title: "Hypohidrotic Ectodermal Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early dental treatment; bonding of conical teeth; orthodontics as
      necessary; dental implants in the anterior portion of the mandibular
      arch in older children; replacement of dental prostheses as needed,
      often every 2.5 years; dental implants in adults
    explanation: >-
      GeneReviews comprehensive dental management strategy for HED.
- name: Genetic Counseling
  description: >-
    Genetic counseling for families to determine inheritance pattern (AR vs AD)
    and recurrence risk. Identification of the specific EDAR pathogenic
    variant enables prenatal and preimplantation genetic testing.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:20301291
    reference_title: "Hypohidrotic Ectodermal Dysplasia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      EDAR-, EDARADD-, and WNT10A-related HED are inherited in an autosomal
      recessive or an autosomal dominant manner.
    explanation: >-
      GeneReviews confirms the dual inheritance pattern requiring careful
      genetic counseling.
  - reference: PMID:32819890
    reference_title: "Homozygous variants of EDAR underlying hypohidrotic ectodermal dysplasia in three consanguineous families."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The three variants reported here expand the spectrum of EDAR mutations
      associated with HED which may further facilitate genetic counselling of
      families segregating with similar disorders in the Pakistani population.
    explanation: >-
      Expanding variant spectrum supports importance of genetic counseling
      in diverse populations.
datasets: []
references:
- reference: PMID:20301291
  title: "Hypohidrotic Ectodermal Dysplasia."
  tags:
  - GeneReviews
📚

References & Deep Research

References

1
PMID:20301291
Hypohidrotic Ectodermal Dysplasia.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 48 citations 2026-04-24T18:18:37.772668

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: EDAR-Related Hypohidrotic Ectodermal Dysplasia
  • MONDO ID: (if available)
  • Category: Genetic

Research Objectives

Please provide a comprehensive research report on EDAR-Related Hypohidrotic Ectodermal Dysplasia covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

EDAR-Related Hypohidrotic Ectodermal Dysplasia (EDAR-HED)

Executive summary

EDAR-related hypohidrotic ectodermal dysplasia (EDAR-HED) is an autosomal dominant or autosomal recessive subtype within the broader group of hypohidrotic/anhidrotic ectodermal dysplasias (HED) characterized by impaired development of ectoderm-derived appendages—classically reduced sweating (hypohidrosis/anhidrosis), sparse hair (hypotrichosis), and missing/malformed teeth (hypodontia/oligodontia). EDAR encodes the ectodysplasin A receptor, a core component of the EDA–EDAR–EDARADD signaling module that activates NF-κB and related pathways during fetal ectodermal organ development. (salasalanis2015mutationsineda pages 1-3, higashino2017advancesinthe pages 12-16, reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2)

A key 2023 mechanistic advance was the determination of the human EDA-A1–EDAR ligand–receptor complex crystal structure, providing an atomic-level explanation of how disease-causing variants disrupt binding and downstream NF-κB signaling. (yu2023structuralinsightsinto pages 1-3, yu2023structuralinsightsinto pages 3-4)

A major 2024 clinical development is the operationalization of phenotype-driven genomic testing strategies (targeted EDA/EDAR first-line for classic triad; WES/WGS and CNV-aware assays for atypical/negative cases), supported by quantitative yield data from a Korean cohort. (kim2024geneticprofilingand pages 1-2, kim2024geneticprofilingand pages 7-8)

Quick reference (identifiers and core facts)

Item Key identifiers and core facts Primary source URL
Disease/term EDAR-related hypohidrotic ectodermal dysplasia (HED); a subset of hypohidrotic ectodermal dysplasia involving pathogenic variants in EDAR; clinically overlaps with broader HED characterized by ectodermal appendage defects (higashino2017advancesinthe pages 12-16, reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2) Higashino et al. 2017; Reyes-Reali et al. 2018 https://doi.org/10.1080/21678707.2017.1405806; https://doi.org/10.1111/ijd.14048
MONDO ID Broad disease: hypohidrotic ectodermal dysplasia = MONDO_0016535; EDAR-related disease maps most directly to autosomal dominant hypohidrotic ectodermal dysplasia = MONDO_0015884 and autosomal recessive hypohidrotic ectodermal dysplasia = MONDO_0016619; Open Targets also lists ectodermal dysplasia 10A, hypohidrotic/hair/nail type, autosomal dominant = MONDO_0007509 for EDAR-associated disease (martinezromero2019edaedaredaradd pages 1-2) Open Targets disease-target associations https://platform.opentargets.org
Gene(s) Core pathway genes: EDAR (ectodysplasin A receptor), EDARADD (EDAR-associated death domain adaptor), EDA (ligand). EDAR is on 2q11-q13; EDAR/EDARADD are autosomal pathway genes, while EDA is X-linked (salasalanis2015mutationsineda pages 1-3, ahmed2021genemutationsof pages 1-2, reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2, martinezromero2019edaedaredaradd pages 1-2) Salas-Alanis et al. 2015; Ahmed et al. 2021; Reyes-Reali et al. 2018; Martínez-Romero et al. 2019 https://doi.org/10.5021/ad.2015.27.4.474; https://doi.org/10.3390/genes12091389; https://doi.org/10.1111/ijd.14048; https://doi.org/10.1186/s13023-019-1251-x
Inheritance patterns HED may be X-linked, autosomal dominant, or autosomal recessive; EDAR-related HED specifically occurs in autosomal dominant and autosomal recessive forms (salasalanis2015mutationsineda pages 1-3, higashino2017advancesinthe pages 12-16, reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2) Salas-Alanis et al. 2015; Higashino et al. 2017; Reyes-Reali et al. 2018 https://doi.org/10.5021/ad.2015.27.4.474; https://doi.org/10.1080/21678707.2017.1405806; https://doi.org/10.1111/ijd.14048
Hallmark triad Hypohidrosis/anhidrosis, hypotrichosis (sparse hair), and hypodontia/anodontia/oligodontia are the cardinal triad; additional features can include dry skin, dry eyes/airways, abnormal tooth shape, frontal bossing, saddle nose, prominent lips, and heat intolerance (salasalanis2015mutationsineda pages 1-3, ahmed2021genemutationsof pages 1-2, reyes‐reali2018hypohidroticectodermaldysplasia pages 2-4, reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2) Salas-Alanis et al. 2015; Ahmed et al. 2021; Reyes-Reali et al. 2018 https://doi.org/10.5021/ad.2015.27.4.474; https://doi.org/10.3390/genes12091389; https://doi.org/10.1111/ijd.14048
Key epidemiology figures from evidence Reported figures vary by source and may reflect different definitions: ectodermal dysplasias overall ~1.6 per 100,000 (kovalskaia2023molecularbasisand pages 2-4); HED prevalence 1–9 per 100,000 births (ahmed2021genemutationsof pages 1-2); XLHED incidence 1/50,000–100,000 males (martinezromero2019edaedaredaradd pages 1-2); XLHED frequency ~1/17,000 live births (reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2); HED ~7 per 10,000 live births reported in one review (higashino2017advancesinthe pages 1-7) Kovalskaia et al. 2023; Ahmed et al. 2021; Martínez-Romero et al. 2019; Reyes-Reali et al. 2018; Higashino et al. 2017 https://doi.org/10.18699/vjgb-23-78; https://doi.org/10.3390/genes12091389; https://doi.org/10.1186/s13023-019-1251-x; https://doi.org/10.1111/ijd.14048; https://doi.org/10.1080/21678707.2017.1405806
Key diagnostic yield stats (Korea cohort, 2024) In 27 Korean ED patients, overall molecular diagnostic yield = 74.1% (20/27); EDA/EDAR variants accounted for 80% of positive cases (16/20); among patients with the complete hair/skin/dental triad, 94.1% (16/17) had detectable EDA/EDAR mutations; among patients lacking the full triad, 0% (0/10) had EDA/EDAR mutations; 23.1% (3/13) of EDA-positive cases had copy-number variants (kim2024geneticprofilingand pages 1-2, kim2024geneticprofilingand pages 7-8, kim2024geneticprofilingand pages 2-4, kim2024geneticprofilingand pages 4-6, kim2024geneticprofilingand pages 6-7) Kim et al. 2024 https://doi.org/10.1186/s13023-024-03331-6
Diagnostic approach implications For classical triad presentations, targeted EDA/EDAR testing is recommended first-line; for atypical/non-triad cases, WES is preferred; CNV-aware methods such as MLPA should be considered when standard sequencing is negative, especially because EDA CNVs can be missed (reyes‐reali2018hypohidroticectodermaldysplasia pages 2-4, kim2024geneticprofilingand pages 1-2, kim2024geneticprofilingand pages 7-8, kim2024geneticprofilingand pages 2-4) Reyes-Reali et al. 2018; Kim et al. 2024 https://doi.org/10.1111/ijd.14048; https://doi.org/10.1186/s13023-024-03331-6
Pathway role EDAR is the receptor in the EDA–EDAR–EDARADD–NF-κB pathway. EDA binds EDAR, EDAR recruits EDARADD, and downstream signaling activates NF-κB/JNK to regulate development of hair follicles, teeth, nails, and eccrine sweat glands; disruption causes HED phenotypes (kovalskaia2023molecularbasisand pages 2-4, higashino2017advancesinthe pages 12-16, reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2) Kovalskaia et al. 2023; Higashino et al. 2017; Reyes-Reali et al. 2018 https://doi.org/10.18699/vjgb-23-78; https://doi.org/10.1080/21678707.2017.1405806; https://doi.org/10.1111/ijd.14048

Table: This table summarizes the main identifiers, inheritance, hallmark features, epidemiology, pathway biology, and diagnostic yield figures relevant to EDAR-related hypohidrotic ectodermal dysplasia. It is useful as a quick reference for disease knowledge-base curation and clinical interpretation.

1. Disease information

1.1 Overview / definition

HED is described as a genetic disorder affecting ectoderm-derived structures (hair, teeth, eccrine sweat glands) and presenting with the classical triad of hypotrichosis, hypohidrosis/anhidrosis, and hypodontia/oligodontia. (salasalanis2015mutationsineda pages 1-3, reyes‐reali2018hypohidroticectodermaldysplasia pages 2-4, reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2)

EDAR-related HED refers to HED caused by pathogenic variants in EDAR (ectodysplasin A receptor), producing autosomal dominant (AD) and autosomal recessive (AR) disease forms that are clinically largely indistinguishable from X-linked EDA-related HED. (salasalanis2015mutationsineda pages 1-3, higashino2017advancesinthe pages 12-16, reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2)

1.2 Key identifiers

  • MONDO (from Open Targets):
  • Hypohidrotic ectodermal dysplasia: MONDO_0016535 (broad concept) (kovalskaia2023molecularbasisand pages 2-4)
  • Autosomal dominant hypohidrotic ectodermal dysplasia: MONDO_0015884 (EDAR can be causal) (kovalskaia2023molecularbasisand pages 2-4)
  • Autosomal recessive hypohidrotic ectodermal dysplasia: MONDO_0016619 (EDAR can be causal) (kovalskaia2023molecularbasisand pages 2-4)

Not retrieved with the available tools in this run: OMIM number(s), Orphanet identifier(s), ICD-10/ICD-11 codes, MeSH terms.

1.3 Synonyms / alternative names

  • Hypohidrotic ectodermal dysplasia (HED)
  • Anhidrotic ectodermal dysplasia / hypohidrotic-anhidrotic ED (used interchangeably in clinical literature) (salasalanis2015mutationsineda pages 1-3, reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2)
  • “ED/EDA” or “HED/EDA1” in some older usage, reflecting historical emphasis on the EDA pathway (reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2)

1.4 Evidence type note (individual patient vs aggregated)

Evidence in the retrieved corpus is primarily aggregated disease-level review synthesis plus cohort-based genetics studies and clinical trial registry records (e.g., diagnostic yields, variant proportions, trial endpoints), rather than EHR-derived real-world datasets. (kim2024geneticprofilingand pages 1-2, NCT04980638 chunk 1, NCT02099552 chunk 1)

2. Etiology

2.1 Disease causal factors

EDAR-HED is a monogenic developmental disorder caused by germline pathogenic variants affecting the EDA signaling pathway. EDAR encodes the receptor for ectodysplasin A (EDA), and EDAR recruits the adaptor EDARADD to activate downstream signaling such as NF-κB and JNK/AP-1, crucial for ectodermal appendage development. (higashino2017advancesinthe pages 12-16, reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2)

EDAR is located on chromosome 2q11–q13 (commonly cited as 2q11-q13 or 2q11–13). (salasalanis2015mutationsineda pages 1-3, ahmed2021genemutationsof pages 1-2, reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2)

2.2 Risk factors

The dominant “risk factor” is inheritance of a pathogenic EDAR variant (AD or AR) or having a family history consistent with these patterns. HED overall can be X-linked, autosomal dominant, or autosomal recessive. (salasalanis2015mutationsineda pages 1-3, reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2)

Population-level observations suggest that consanguinity may increase the contribution of autosomal recessive forms in some cohorts. (ahmed2021genemutationsof pages 1-2, guven2019turkishectodermaldysplasia pages 5-6)

2.3 Protective factors and gene–environment interactions

No protective genetic variants or robust gene–environment interaction mechanisms specific to EDAR-HED were identified in the retrieved sources.

3. Phenotypes

3.1 Core phenotypes and typical timing

HED is typically congenital/early-onset, though clinical diagnosis may be made “after infancy” once ectodermal features are evident. (reyes‐reali2018hypohidroticectodermaldysplasia pages 2-4)

The cardinal triad is: - Reduced sweating (hypohidrosis/anhidrosis) (salasalanis2015mutationsineda pages 1-3, reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2) - Sparse/abnormal hair (hypotrichosis) (salasalanis2015mutationsineda pages 1-3, reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2) - Missing/malformed teeth (hypodontia/oligodontia; abnormal tooth shape) (salasalanis2015mutationsineda pages 1-3, ahmed2021genemutationsof pages 1-2)

3.2 Additional features and complications

Reported additional manifestations include dryness of skin/eyes/airways/mucous membranes; characteristic craniofacial features (e.g., frontal bossing, saddle nose, prominent lips); and in some cases fever, seizures, and rarely death (likely related to thermoregulation and systemic complications). (salasalanis2015mutationsineda pages 1-3, ahmed2021genemutationsof pages 1-2)

3.3 Quantitative phenotype-linked statistics (proxy for frequency)

A practical, clinically relevant “frequency” estimate comes from molecular-diagnostic stratification: - In a Korean ectodermal dysplasia cohort (2018–2022), 94.1% (16/17) of patients manifesting the complete hair/skin/dental triad had detectable EDA/EDAR mutations, versus 0% (0/10) among those without the full triad; overall diagnostic yield was 74.1% (20/27). (kim2024geneticprofilingand pages 1-2, kim2024geneticprofilingand pages 7-8)

3.4 Quality of life (QoL)

Direct validated QoL scores (e.g., SF-36, EQ-5D, PROMIS) for EDAR-HED were not present in the retrieved evidence; however, trial outcomes and observational endpoints emphasize clinically meaningful impacts including thermoregulation, dry eye, salivation, eczema severity, and hospitalizations. (NCT04980638 chunk 1, NCT02099552 chunk 1)

3.5 Suggested HPO terms (non-exhaustive)

  • Hypohidrosis: HP:0000971
  • Anhidrosis: HP:0000970
  • Hypotrichosis: HP:0001006
  • Hypodontia: HP:0000668
  • Oligodontia: HP:0000677
  • Conical teeth: HP:0000691
  • Heat intolerance: HP:0002046
  • Xerosis cutis (dry skin): HP:0000958

4. Genetic / molecular information

4.1 Causal genes and pathway

  • EDAR (ectodysplasin A receptor): receptor for EDA-A1; can cause both AD- and AR-HED. (higashino2017advancesinthe pages 12-16, reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2)
  • EDARADD: adaptor protein interacting with EDAR; part of the EDAR signaling complex. (higashino2017advancesinthe pages 12-16, salasalanis2015mutationsineda pages 1-3)
  • EDA: ligand (classically X-linked HED), but mechanistically central to EDAR activation. (salasalanis2015mutationsineda pages 1-3, reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2)

4.2 Pathogenic variant classes (EDAR)

A review summarizes that >50 EDAR mutations have been reported, predominantly missense/nonsense, with additional deletions, splice changes, insertions, and indels. (higashino2017advancesinthe pages 12-16)

4.3 Recent mechanistic advance (2023): atomic structure of EDA-A1–EDAR complex

Yu et al. (Nature Communications, Feb 2023, URL: https://doi.org/10.1038/s41467-023-36367-6) solved the EDA·A1 TNF homology domain (THD) bound to EDAR cysteine-rich domains (CRDs), providing a structural basis for ligand–receptor specificity and for interpreting pathogenic variants. (yu2023structuralinsightsinto pages 1-3)

Key findings include: - A heterohexameric architecture (EDA trimer with three EDAR CRDs), solved at 2.8 Å; binding affinity KD ≈ 18.5 nM by SPR. (yu2023structuralinsightsinto pages 3-4) - Interface-pathogenic variants (e.g., A259E, D265G) can abolish interaction and reduce downstream signaling readouts (NF-κB reporter), explaining graded phenotypic severity. (yu2023structuralinsightsinto pages 4-6, yu2023structuralinsightsinto pages 7-9)

Visual evidence

Figure depicting the EDA-A1–EDAR complex structure and domain organization (Yu et al., 2023): (yu2023structuralinsightsinto media b524539c)

4.4 Modifier genes / epigenetics / chromosomal abnormalities

No EDAR-HED-specific modifier genes, epigenetic mechanisms, or recurrent chromosomal abnormalities were identified in the retrieved sources.

5. Environmental information

HED/EDAR-HED is primarily genetic. The retrieved sources focus on congenital developmental mechanisms rather than environmental triggers; no specific toxins, infections, lifestyle factors, or GxE interactions were supported by the retrieved evidence.

6. Mechanism / pathophysiology

6.1 Causal chain (upstream → downstream)

  1. Ligand–receptor step: EDA (especially isoform EDA-A1) binds EDAR. (higashino2017advancesinthe pages 12-16, reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2)
  2. Signalosome assembly: EDAR recruits EDARADD and activates downstream signaling including NF-κB and JNK/AP-1. (higashino2017advancesinthe pages 12-16)
  3. Developmental outcome: signaling drives epithelial–mesenchymal communication necessary for initiation/morphogenesis/differentiation of ectodermal organs (hair follicles, teeth, sweat glands, nails). (reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2)
  4. Clinical phenotype: impaired organogenesis yields the triad (hypohidrosis, hypotrichosis, hypodontia) and associated complications (dryness, heat intolerance, infections). (salasalanis2015mutationsineda pages 1-3, ahmed2021genemutationsof pages 1-2)

6.2 Suggested GO biological process terms

  • NF-kappaB signaling: GO:0043122 (regulation of IκB kinase/NF-κB signaling)
  • Epithelial–mesenchymal signaling involved in organ morphogenesis: GO:0002009 (morphogenesis of an epithelium) / GO:0007423 (sensory organ development; for teeth/hair specialized ontologies may also apply)
  • Hair follicle development: GO:0001942
  • Tooth development: GO:0042476
  • Sweat gland development: (may require more specific GO mapping depending on ontology versions)

6.3 Suggested CL cell types (examples)

  • Keratinocyte: CL:0000312 (epidermal keratinocyte)
  • Dermal fibroblast / mesenchymal progenitors: e.g., fibroblast CL:0000057

6.4 Suggested UBERON anatomical structures

  • Eccrine sweat gland: UBERON:0002789
  • Tooth: UBERON:0001091
  • Hair follicle: UBERON:0002075
  • Skin: UBERON:0002097

7. Anatomical structures affected

Primary involvement includes ectoderm-derived appendages and glands: hair follicles, teeth, eccrine sweat glands, and other exocrine structures (lacrimal/salivary/bronchial glands highlighted in translational studies). (salasalanis2015mutationsineda pages 1-3, higashino2017advancesinthe pages 26-30)

8. Temporal development

The disorder is developmental/congenital, though clinical recognition may become apparent after infancy when ectodermal features can be assessed. (reyes‐reali2018hypohidroticectodermaldysplasia pages 2-4)

A key therapeutic implication of the developmental timing is that earlier treatment (prenatal/perinatal) appears more effective at rescuing organ development than later postnatal administration in models and early trials. (higashino2017advancesinthe pages 26-30)

9. Inheritance and population

9.1 Inheritance

HED occurs in X-linked, autosomal dominant, and autosomal recessive forms; EDAR is implicated in AD and AR forms. (salasalanis2015mutationsineda pages 1-3, reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2)

9.2 Epidemiology (reported ranges; heterogeneous definitions)

Reported figures from the retrieved literature include: - Ectodermal dysplasias overall: ~1.6 per 100,000 (kovalskaia2023molecularbasisand pages 2-4) - HED prevalence: 1–9 per 100,000 births (ahmed2021genemutationsof pages 1-2) - XLHED incidence: 1/50,000–100,000 males (martinezromero2019edaedaredaradd pages 1-2) - XLHED frequency: ~1 per 17,000 live births (reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2) - HED: ~7 per 10,000 live births (higashino2017advancesinthe pages 1-7)

These estimates are not EDAR-specific and likely reflect different ascertainment and subtype definitions. (higashino2017advancesinthe pages 1-7, ahmed2021genemutationsof pages 1-2)

9.3 Population genetics signals for EDAR (cohort-based)

  • In a Spanish cohort, EDAR variants comprised 7.8% (4/51) of genetically solved cases. (martinezromero2019edaedaredaradd pages 2-4)
  • In an Egyptian cohort, EDAR accounted for ~5% of identified molecular causes. (ahmed2021genemutationsof pages 1-2)
  • A Russian cohort reported recurrent EDAR alleles in multiple unrelated patients, suggesting regional enrichment (founder/recurrent effects), although formal founder analysis is not provided in the excerpt. (kovalskaia2026mutationalspectrumof pages 6-7)

10. Diagnostics

10.1 Clinical recognition and functional testing

  • Sweat testing: starch–iodine testing can demonstrate hypohidrosis/anhidrosis; in affected individuals, the test can show “scarcity or absence of purple color,” while normal subjects develop purple coloration. (reyes‐reali2018hypohidroticectodermaldysplasia pages 2-4)
  • Histopathology: biopsy can show orthokeratotic hypertrophy of stratum corneum and atrophic/immature eccrine sweat glands. (reyes‐reali2018hypohidroticectodermaldysplasia pages 2-4)

Additional sweat quantification methods and objective measures noted in a differential-diagnosis resource include pilocarpine-induced sweat measurement and sweat pore density assessment. (peschel2024differentialdiagnostischeeinordnungektodermaler pages 23-25)

10.2 Molecular confirmation (EDAR-relevant)

A diagnostic confirmation rule described in a clinical/molecular review: diagnosis can be confirmed by finding a hemizygous EDA variant in an affected male or biallelic EDAR/EDARADD/WNT10A pathogenic variants in an affected individual, consistent with autosomal recessive inheritance for those genes. (reyes‐reali2018hypohidroticectodermaldysplasia pages 2-4)

10.3 Testing strategy (recent implementation guidance, 2024)

In a Korean cohort (Orphanet Journal of Rare Diseases, Sep 2024, URL: https://doi.org/10.1186/s13023-024-03331-6), diagnostic yield data support: - Targeted EDA/EDAR sequencing as first-line when the classical hair/skin/dental triad is present (high yield: 94.1%). (kim2024geneticprofilingand pages 6-7, kim2024geneticprofilingand pages 7-8) - WES for cases lacking classic triad or with atypical involvement. (kim2024geneticprofilingand pages 7-8) - Considering CNV/structural variant detection (e.g., MLPA, WGS) when classic phenotype is present but sequencing is negative, since CNVs may be missed. (kim2024geneticprofilingand pages 7-8)

A Spanish cohort similarly used Sanger sequencing plus MLPA across EDA/EDAR/EDARADD/WNT10A and emphasized the need for NGS to solve remaining cases. (martinezromero2019edaedaredaradd pages 1-2)

10.4 Differential diagnosis (syndromic overlaps)

Differential diagnosis includes other ED syndromes and ED-like disorders (e.g., TP63-related syndromes, IKBKG/NEMO-related immunodeficiency-associated ED, and other hair/tooth disorders). (higashino2017advancesinthe pages 16-21)

11. Outcome / prognosis

Specific EDAR-HED survival estimates were not identified in the retrieved sources. The retrieved clinical literature emphasizes morbidity related to thermoregulation, mucosal dryness, ocular and respiratory involvement, and dental function; these domains are reflected in natural history and clinical trial endpoints. (NCT04980638 chunk 1, NCT02099552 chunk 1)

12. Treatment

12.1 Current real-world management (supportive)

Supportive care is multidisciplinary and may include: - Thermoregulation and heat-illness prevention strategies (inferred by emphasis on hypohidrosis/anhidrosis risk and early diagnosis). (higashino2017advancesinthe pages 12-16) - Dental rehabilitation planning for hypodontia/oligodontia (not quantitatively detailed in the retrieved excerpts). - Management of dry eye and other glandular dysfunction, reflected in trial outcome selection. (NCT04980638 chunk 1)

12.2 Disease-modifying / developmental therapies (clinical trials; largely XLHED-focused but pathway-relevant)

Although EDAR-HED is EDAR-driven and many interventional programs target EDA replacement (primarily XLHED), these efforts represent the most advanced pathway-directed translational work and are mechanistically relevant to EDAR signaling.

Prenatal/perinatal EDA-A1 replacement (ER004/EDI200): - ClinicalTrials.gov NCT04980638 (EspeRare Foundation; Phase 2; recruiting as of the record): intra-amniotic ER004 to male fetuses with XLHED; dosing 100 mg/kg estimated fetal weight per injection, three injections beginning at gestational week 26; primary endpoint mean sweat volume at 6 months; secondary endpoints include sweat pore density, dentition (erupted teeth, tooth germs), Meibomian glands, ocular surface, salivation, eczema severity (EASI), hospitalizations, and safety. (NCT04980638 chunk 1)

Neonatal dosing trial: - ClinicalTrials.gov NCT01775462 (Edimer Pharmaceuticals; Phase 2; completed): open-label dose-escalation EDI200 given to male neonates (48 hours to 14 days) with efficacy endpoints including dentition, craniofacial development, sweat duct density, sweat rate, dry eye measures, thermoregulation, and skin biopsy expression profiles. (NCT01775462 chunk 1)

Adult safety/PK trial: - ClinicalTrials.gov NCT01564225 (Edimer Pharmaceuticals; Phase 1; completed): adults with XLHED, focusing on safety/PK and exploratory ectodermal outcomes (hair, sweat duct density/rate, salivation, tearing, pulmonary markers). (NCT01564225 chunk 1)

Expert analysis (timing as critical): A translational review notes that in models, prenatal/intra-amniotic delivery can rescue development more effectively, whereas postnatal human dosing showed limited improvements and was considered “too late” for certain structures. (higashino2017advancesinthe pages 26-30)

12.3 Suggested MAXO terms (examples)

  • Genetic testing: MAXO:0000127 (genetic test)
  • Prenatal therapy / intra-amniotic drug administration: (MAXO mapping depends on the MAXO version; candidate: intra-amniotic administration)
  • Protein replacement therapy (for ectodysplasin A1 replacement)
  • Dental prosthetic rehabilitation / dental restoration (for hypodontia)

13. Prevention

Primary prevention of EDAR-HED is not currently feasible biologically (genetic etiology). Secondary/tertiary prevention focuses on early diagnosis to mitigate overheating risk and manage dental/ocular/skin complications, supported by recommendations for early genetic diagnosis and phenotype-driven testing. (higashino2017advancesinthe pages 12-16, kim2024geneticprofilingand pages 7-8)

Genetic counseling and prenatal diagnosis options are discussed in clinical reviews, including invasive prenatal testing options with counseling. (morandini2025ectodermaldysplasiaa pages 6-7)

14. Other species / natural disease

A translational review describes a naturally occurring canine X-linked HED model that closely mirrors human ectodermal phenotypes (absence of sweat glands; dental and bronchial gland abnormalities; infections), supporting comparative pathology and therapy testing. (higashino2017advancesinthe pages 26-30)

15. Model organisms

15.1 Mouse models (mechanism and therapy testing)

  • Tabby mouse (EDA-deficient) is a canonical model for HED, with phenotypes in teeth, sweat glands, and hair, and is used to test EDA replacement and anti-EDAR agonist antibodies. (higashino2017advancesinthe pages 26-30, higashino2017advancesinthe pages 21-26)
  • CRISPR-engineered Eda point-mutant mice (A259E, D265G, R276C) show graded phenotypes consistent with human severity differences; severe defects include loss of eccrine sweat glands and dental agenesis in knockout and D265G models. (yu2023structuralinsightsinto pages 7-9)

15.2 Canine model

A canine XLHED model is emphasized as phenotypically closer to humans than mice (notably secondary dentition and glandular phenotypes) and was used to evaluate postnatal EDA replacement effects on secondary dentition and glands. (higashino2017advancesinthe pages 26-30)

Evidence gaps and limitations of this tool run

  1. PMIDs: Many retrieved excerpts did not include PubMed IDs explicitly; therefore, PMIDs could not be reliably listed for most claims despite being derived from peer-reviewed articles. URLs/DOIs and publication months/years are provided where available. (yu2023structuralinsightsinto pages 1-3, kim2024geneticprofilingand pages 1-2)
  2. Disease identifiers: OMIM/Orphanet/ICD/MeSH identifiers were not retrievable with the currently available tools.
  3. EDAR-specific epidemiology: Most prevalence/incidence statistics are reported for HED overall or XLHED, not specifically EDAR-HED.

Key references (most relevant, recent/high-authority)

  • Yu K et al. Nature Communications (Feb 2023). “Structural insights into pathogenic mechanism of hypohidrotic ectodermal dysplasia caused by ectodysplasin A variants.” https://doi.org/10.1038/s41467-023-36367-6 (yu2023structuralinsightsinto pages 1-3)
  • Kim MJ et al. Orphanet Journal of Rare Diseases (Sep 2024). “Genetic profiling and diagnostic strategies for patients with ectodermal dysplasias in Korea.” https://doi.org/10.1186/s13023-024-03331-6 (kim2024geneticprofilingand pages 1-2)
  • ClinicalTrials.gov NCT04980638 (ER004 intra-amniotic; Phase 2). https://clinicaltrials.gov/study/NCT04980638 (NCT04980638 chunk 1)
  • Reyes-Reali J et al. International Journal of Dermatology (May 2018). Clinical/molecular review and diagnostic testing. https://doi.org/10.1111/ijd.14048 (reyes‐reali2018hypohidroticectodermaldysplasia pages 2-4)
  • Martínez-Romero MC et al. Orphanet Journal of Rare Diseases (Dec 2019). Spain cohort sequencing + MLPA. https://doi.org/10.1186/s13023-019-1251-x (martinezromero2019edaedaredaradd pages 1-2)

References

  1. (salasalanis2015mutationsineda pages 1-3): Julio C Salas-Alanis, Eva Wozniak, Charles A Mein, Carola C Duran Mckinster, Jorge Ocampo-Candiani, David P Kelsell, Rong Hua, Maria L Garza-Rodriguez, Keith A Choate, and Hugo A Barrera Saldaña. Mutations in eda and edar genes in a large mexican hispanic cohort with hypohidrotic ectodermal dysplasia. Annals of Dermatology, 27:474-477, Jul 2015. URL: https://doi.org/10.5021/ad.2015.27.4.474, doi:10.5021/ad.2015.27.4.474. This article has 23 citations and is from a peer-reviewed journal.

  2. (higashino2017advancesinthe pages 12-16): Toshihide Higashino, John Y. W. Lee, and John A. McGrath. Advances in the genetic understanding of hypohidrotic ectodermal dysplasia. Expert Opinion on Orphan Drugs, 5:967-975, Nov 2017. URL: https://doi.org/10.1080/21678707.2017.1405806, doi:10.1080/21678707.2017.1405806. This article has 2 citations.

  3. (reyes‐reali2018hypohidroticectodermaldysplasia pages 1-2): Julia Reyes‐Reali, María Isabel Mendoza‐Ramos, Efraín Garrido‐Guerrero, Claudia F. Méndez‐Catalá, Adolfo R. Méndez‐Cruz, and Glustein Pozo‐Molina. Hypohidrotic ectodermal dysplasia: clinical and molecular review. International Journal of Dermatology, 57:965-972, May 2018. URL: https://doi.org/10.1111/ijd.14048, doi:10.1111/ijd.14048. This article has 124 citations and is from a peer-reviewed journal.

  4. (yu2023structuralinsightsinto pages 1-3): Kang Yu, Chenhui Huang, Futang Wan, Cailing Jiang, Juan Chen, Xiuping Li, Feng Wang, Jian Wu, Ming Lei, and Yiqun Wu. Structural insights into pathogenic mechanism of hypohidrotic ectodermal dysplasia caused by ectodysplasin a variants. Nature Communications, Feb 2023. URL: https://doi.org/10.1038/s41467-023-36367-6, doi:10.1038/s41467-023-36367-6. This article has 28 citations and is from a highest quality peer-reviewed journal.

  5. (yu2023structuralinsightsinto pages 3-4): Kang Yu, Chenhui Huang, Futang Wan, Cailing Jiang, Juan Chen, Xiuping Li, Feng Wang, Jian Wu, Ming Lei, and Yiqun Wu. Structural insights into pathogenic mechanism of hypohidrotic ectodermal dysplasia caused by ectodysplasin a variants. Nature Communications, Feb 2023. URL: https://doi.org/10.1038/s41467-023-36367-6, doi:10.1038/s41467-023-36367-6. This article has 28 citations and is from a highest quality peer-reviewed journal.

  6. (kim2024geneticprofilingand pages 1-2): Man Jin Kim, Jee-Soo Lee, Seung Won Chae, Sung Im Cho, Jangsup Moon, Jung Min Ko, Jong-Hee Chae, and Moon-Woo Seong. Genetic profiling and diagnostic strategies for patients with ectodermal dysplasias in korea. Orphanet Journal of Rare Diseases, Sep 2024. URL: https://doi.org/10.1186/s13023-024-03331-6, doi:10.1186/s13023-024-03331-6. This article has 1 citations and is from a peer-reviewed journal.

  7. (kim2024geneticprofilingand pages 7-8): Man Jin Kim, Jee-Soo Lee, Seung Won Chae, Sung Im Cho, Jangsup Moon, Jung Min Ko, Jong-Hee Chae, and Moon-Woo Seong. Genetic profiling and diagnostic strategies for patients with ectodermal dysplasias in korea. Orphanet Journal of Rare Diseases, Sep 2024. URL: https://doi.org/10.1186/s13023-024-03331-6, doi:10.1186/s13023-024-03331-6. This article has 1 citations and is from a peer-reviewed journal.

  8. (martinezromero2019edaedaredaradd pages 1-2): M. C. Martínez-Romero, M. Ballesta-Martínez, V. López‐González, M. J. Sánchez-Soler, A. T. Serrano-Antón, M. Barreda-Sánchez, L. Rodríguez-Peña, M. T. Martínez-Menchon, J. Frías-Iniesta, P. Sánchez‐Pedreño, Pablo Carbonell-Meseguer, G. Glover-López, E. Guillén-Navarro, Rebeca Ana Jaime Blanca Angela Pablo Isabel Sabel Antonio Alcalá-García Barcia-Ramírez Cruz-Rojo Gener-Quero, Rebeca Alcalá-García, Ana Barcia-Ramírez, J. Cruz-Rojo, Blanca Gener-Querol, Á. Hernández-Martín, Pablo Lapunzina-Badía, Isabel Llanos-Rivas, Sabel Lorda-Sánchez, Antonio Martínez-Carrascal, J. Mascaró-Galy, L. Noguera‐Morel, M. A. Rodríguez-González, J. S. del Pozo, Verónica Seidel, A. Torrelo, and M. Trujillo-Tiebas. Eda, edar, edaradd and wnt10a allelic variants in patients with ectodermal derivative impairment in the spanish population. Orphanet Journal of Rare Diseases, Dec 2019. URL: https://doi.org/10.1186/s13023-019-1251-x, doi:10.1186/s13023-019-1251-x. This article has 53 citations and is from a peer-reviewed journal.

  9. (ahmed2021genemutationsof pages 1-2): Hoda A. Ahmed, Ghada Y. El-Kamah, Eman Rabie, Mostafa I. Mostafa, Maha R. Abouzaid, Nehal F. Hassib, Mennat I. Mehrez, Mohamed A. Abdel-Kader, Yasmine H. Mohsen, Suher K. Zada, Khalda S. Amr, and Inas S. M. Sayed. Gene mutations of the three ectodysplasin pathway key players (eda, edar, and edaradd) account for more than 60% of egyptian ectodermal dysplasia: a report of seven novel mutations. Genes, 12:1389, Sep 2021. URL: https://doi.org/10.3390/genes12091389, doi:10.3390/genes12091389. This article has 26 citations.

  10. (reyes‐reali2018hypohidroticectodermaldysplasia pages 2-4): Julia Reyes‐Reali, María Isabel Mendoza‐Ramos, Efraín Garrido‐Guerrero, Claudia F. Méndez‐Catalá, Adolfo R. Méndez‐Cruz, and Glustein Pozo‐Molina. Hypohidrotic ectodermal dysplasia: clinical and molecular review. International Journal of Dermatology, 57:965-972, May 2018. URL: https://doi.org/10.1111/ijd.14048, doi:10.1111/ijd.14048. This article has 124 citations and is from a peer-reviewed journal.

  11. (kovalskaia2023molecularbasisand pages 2-4): V. A. Kovalskaia, T. Cherevatova, A. V. Polyakov, and O. P. Ryzhkova. Molecular basis and genetics of hypohidrotic ectodermal dysplasias. Vavilov Journal of Genetics and Breeding, 27:676-683, Nov 2023. URL: https://doi.org/10.18699/vjgb-23-78, doi:10.18699/vjgb-23-78. This article has 6 citations.

  12. (higashino2017advancesinthe pages 1-7): Toshihide Higashino, John Y. W. Lee, and John A. McGrath. Advances in the genetic understanding of hypohidrotic ectodermal dysplasia. Expert Opinion on Orphan Drugs, 5:967-975, Nov 2017. URL: https://doi.org/10.1080/21678707.2017.1405806, doi:10.1080/21678707.2017.1405806. This article has 2 citations.

  13. (kim2024geneticprofilingand pages 2-4): Man Jin Kim, Jee-Soo Lee, Seung Won Chae, Sung Im Cho, Jangsup Moon, Jung Min Ko, Jong-Hee Chae, and Moon-Woo Seong. Genetic profiling and diagnostic strategies for patients with ectodermal dysplasias in korea. Orphanet Journal of Rare Diseases, Sep 2024. URL: https://doi.org/10.1186/s13023-024-03331-6, doi:10.1186/s13023-024-03331-6. This article has 1 citations and is from a peer-reviewed journal.

  14. (kim2024geneticprofilingand pages 4-6): Man Jin Kim, Jee-Soo Lee, Seung Won Chae, Sung Im Cho, Jangsup Moon, Jung Min Ko, Jong-Hee Chae, and Moon-Woo Seong. Genetic profiling and diagnostic strategies for patients with ectodermal dysplasias in korea. Orphanet Journal of Rare Diseases, Sep 2024. URL: https://doi.org/10.1186/s13023-024-03331-6, doi:10.1186/s13023-024-03331-6. This article has 1 citations and is from a peer-reviewed journal.

  15. (kim2024geneticprofilingand pages 6-7): Man Jin Kim, Jee-Soo Lee, Seung Won Chae, Sung Im Cho, Jangsup Moon, Jung Min Ko, Jong-Hee Chae, and Moon-Woo Seong. Genetic profiling and diagnostic strategies for patients with ectodermal dysplasias in korea. Orphanet Journal of Rare Diseases, Sep 2024. URL: https://doi.org/10.1186/s13023-024-03331-6, doi:10.1186/s13023-024-03331-6. This article has 1 citations and is from a peer-reviewed journal.

  16. (NCT04980638 chunk 1): Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal Dysplasia. EspeRare Foundation. 2022. ClinicalTrials.gov Identifier: NCT04980638

  17. (NCT02099552 chunk 1): Natural History and Outcomes in X-Linked Hypohidrotic Ectodermal Dysplasia. Edimer Pharmaceuticals. 2014. ClinicalTrials.gov Identifier: NCT02099552

  18. (guven2019turkishectodermaldysplasia pages 5-6): Yeliz Güven, Elodie Bal, Umut Altunoglu, Esra Yücel, Smail Hadj-Rabia, Mine Koruyucu, Elif Bahar Tuna, Şule Çıldır, Oya Aktören, Christine Bodemer, Zehra O. Uyguner, Asma Smahi, and Hülya Kayserili. Turkish ectodermal dysplasia cohort: from phenotype to genotype in 17 families. Cytogenetic and Genome Research, 157:189-196, Apr 2019. URL: https://doi.org/10.1159/000499325, doi:10.1159/000499325. This article has 19 citations and is from a peer-reviewed journal.

  19. (yu2023structuralinsightsinto pages 4-6): Kang Yu, Chenhui Huang, Futang Wan, Cailing Jiang, Juan Chen, Xiuping Li, Feng Wang, Jian Wu, Ming Lei, and Yiqun Wu. Structural insights into pathogenic mechanism of hypohidrotic ectodermal dysplasia caused by ectodysplasin a variants. Nature Communications, Feb 2023. URL: https://doi.org/10.1038/s41467-023-36367-6, doi:10.1038/s41467-023-36367-6. This article has 28 citations and is from a highest quality peer-reviewed journal.

  20. (yu2023structuralinsightsinto pages 7-9): Kang Yu, Chenhui Huang, Futang Wan, Cailing Jiang, Juan Chen, Xiuping Li, Feng Wang, Jian Wu, Ming Lei, and Yiqun Wu. Structural insights into pathogenic mechanism of hypohidrotic ectodermal dysplasia caused by ectodysplasin a variants. Nature Communications, Feb 2023. URL: https://doi.org/10.1038/s41467-023-36367-6, doi:10.1038/s41467-023-36367-6. This article has 28 citations and is from a highest quality peer-reviewed journal.

  21. (yu2023structuralinsightsinto media b524539c): Kang Yu, Chenhui Huang, Futang Wan, Cailing Jiang, Juan Chen, Xiuping Li, Feng Wang, Jian Wu, Ming Lei, and Yiqun Wu. Structural insights into pathogenic mechanism of hypohidrotic ectodermal dysplasia caused by ectodysplasin a variants. Nature Communications, Feb 2023. URL: https://doi.org/10.1038/s41467-023-36367-6, doi:10.1038/s41467-023-36367-6. This article has 28 citations and is from a highest quality peer-reviewed journal.

  22. (higashino2017advancesinthe pages 26-30): Toshihide Higashino, John Y. W. Lee, and John A. McGrath. Advances in the genetic understanding of hypohidrotic ectodermal dysplasia. Expert Opinion on Orphan Drugs, 5:967-975, Nov 2017. URL: https://doi.org/10.1080/21678707.2017.1405806, doi:10.1080/21678707.2017.1405806. This article has 2 citations.

  23. (martinezromero2019edaedaredaradd pages 2-4): M. C. Martínez-Romero, M. Ballesta-Martínez, V. López‐González, M. J. Sánchez-Soler, A. T. Serrano-Antón, M. Barreda-Sánchez, L. Rodríguez-Peña, M. T. Martínez-Menchon, J. Frías-Iniesta, P. Sánchez‐Pedreño, Pablo Carbonell-Meseguer, G. Glover-López, E. Guillén-Navarro, Rebeca Ana Jaime Blanca Angela Pablo Isabel Sabel Antonio Alcalá-García Barcia-Ramírez Cruz-Rojo Gener-Quero, Rebeca Alcalá-García, Ana Barcia-Ramírez, J. Cruz-Rojo, Blanca Gener-Querol, Á. Hernández-Martín, Pablo Lapunzina-Badía, Isabel Llanos-Rivas, Sabel Lorda-Sánchez, Antonio Martínez-Carrascal, J. Mascaró-Galy, L. Noguera‐Morel, M. A. Rodríguez-González, J. S. del Pozo, Verónica Seidel, A. Torrelo, and M. Trujillo-Tiebas. Eda, edar, edaradd and wnt10a allelic variants in patients with ectodermal derivative impairment in the spanish population. Orphanet Journal of Rare Diseases, Dec 2019. URL: https://doi.org/10.1186/s13023-019-1251-x, doi:10.1186/s13023-019-1251-x. This article has 53 citations and is from a peer-reviewed journal.

  24. (kovalskaia2026mutationalspectrumof pages 6-7): Valeriia A. Kovalskaia, Tatiana B. Cherevatova, Elena V. Zinina, Olga A. Shagina, Ekaterina O. Vorontsova, Galina N. Matyushchenko, Nina A. Demina, Marina P. Petukhova, Tatiana V. Markova, Daria M. Guseva, Varvara A. Galkina, Inga V. Anisimova, Anna A. Stepanova, Alena L. Chuhrova, Margarita V. Sharova, Fatima M. Bostanova, Anahit E. Voskanyan, Aleksander V. Polyakov, and Oxana P. Ryzhkova. Mutational spectrum of eda, edar, edaradd, and wnt10a genes in the largest cohort of russian patients with hypohidrotic ectodermal dysplasia. Orphanet Journal of Rare Diseases, Feb 2026. URL: https://doi.org/10.1186/s13023-026-04211-x, doi:10.1186/s13023-026-04211-x. This article has 0 citations and is from a peer-reviewed journal.

  25. (peschel2024differentialdiagnostischeeinordnungektodermaler pages 23-25): Nicolai Peschel. Differentialdiagnostische einordnung ektodermaler dysplasien auf der basis molekularer signalwege. Text, Jan 2024. URL: https://doi.org/10.25593/open-fau-805, doi:10.25593/open-fau-805. This article has 0 citations and is from a peer-reviewed journal.

  26. (higashino2017advancesinthe pages 16-21): Toshihide Higashino, John Y. W. Lee, and John A. McGrath. Advances in the genetic understanding of hypohidrotic ectodermal dysplasia. Expert Opinion on Orphan Drugs, 5:967-975, Nov 2017. URL: https://doi.org/10.1080/21678707.2017.1405806, doi:10.1080/21678707.2017.1405806. This article has 2 citations.

  27. (NCT01775462 chunk 1): Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED). Edimer Pharmaceuticals. 2013. ClinicalTrials.gov Identifier: NCT01775462

  28. (NCT01564225 chunk 1): A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200. Edimer Pharmaceuticals. 2012. ClinicalTrials.gov Identifier: NCT01564225

  29. (morandini2025ectodermaldysplasiaa pages 6-7): Ana Carolina Morandini, Oluwatomisin Adeogun, Megan Black, Emily Holman, Kaitlyn Collins, Wesley James, Laura Lally, Ashley Fordyce, Rachel Dobbs, Eve McDaniel, Hannah Putnam, and Michael Milano. Ectodermal dysplasia: a narrative review of the clinical and biological aspects relevant to oral health. Frontiers in Pediatrics, Feb 2025. URL: https://doi.org/10.3389/fped.2025.1523313, doi:10.3389/fped.2025.1523313. This article has 3 citations.

  30. (higashino2017advancesinthe pages 21-26): Toshihide Higashino, John Y. W. Lee, and John A. McGrath. Advances in the genetic understanding of hypohidrotic ectodermal dysplasia. Expert Opinion on Orphan Drugs, 5:967-975, Nov 2017. URL: https://doi.org/10.1080/21678707.2017.1405806, doi:10.1080/21678707.2017.1405806. This article has 2 citations.